EPO intends to grant APOSEC patent for treatment of systemic conditions

We are pleased to announce that the European Patent Office informed us of its intention to grant our patent application 09795982.9 concerning the treatment of internal conditions with PBMC (Peripheral Blood Mononuclear Cells).

The patent concerning the treatment of internal inflammatory skin conditions with APOSEC has already been granted by the EPO in July 2013, patent number: 2379085